| Name | Title | Contact Details |
|---|
Ingles Market, Inc. is a Albemarle, NC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Advance Pharmacy Services , WV is a Charleston, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.
Mirum Pharmaceuticals (NASDAQ: MIRM) is dedicated to creating life-changing therapies for patients with liver diseases. We are advancing our lead product candidate for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) — conditions with a profound and devastating impact on quality of life for young patients and their families. Untreated, these conditions can lead to liver failure and inflict life-altering symptoms including stunted growth and severe, non-stop itching. Under current standard of care, patients often require a liver transplant and are at higher risk of many serious health issues. Working closely with patients and caregiver communities, we intimately understand the challenges of living with cholestatic liver diseases. Based on a wealth of data from clinical trials spanning multiple years and involving more than one hundred patients, we believe our approach can address the underlying cause of symptoms and liver damage. Our goal is to give families their lives back.
The Mundipharma story, spanning over six decades, is one that brings together a visionary approach and a pioneering spirit – and is best told through our patients, our employees and the communities in which we serve. Our dedication to putting patients at the heart of every business decision has ensured that we continue to grow and more importantly, improve the lives of the people who need our medicines the most. That foundation has not only delivered significant results, but is a reflection of our ability to convert entrepreneurism and innovation into business success. We are focused on the transformation of Mundipharma`s business in the important Emerging Markets – by leveraging our global leadership in pain and through a shared spirit of innovation, we are building a growing presence in antisepsis, respiratory, oncology, consumer healthcare and other specialty areas. Our unique approach to partnerships has given us the opportunity to establish a strong market presence that covers the world`s pharmaceutical markets. Today we are an innovative company, with more than 4,500 employees across the Emerging Markets and a distribution network covering six continents. And this is just the beginning of our story in this region.